ribonuclease A family member 12 (inactive)Genealiases: HEL-S-85p · RAI1
Q-omics provides the consensus-scored RNASE12 profile across patient tissues and cancer cell-line models. RNASE12 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, RNASE12 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RNASE12 RNA expression shows 5,694 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight LAML, BRCA, and UCEC as cancer lineages where RNASE12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE12 survival associations across molecular data types. RNASE12 RNA expression shows survival associations in the most cancer types (5), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE12 RNA expression–survival associations across cancer types. High RNASE12 expression shows unfavorable associations in LAML, STAD, BLCA, LGG and LIHC. The LAML Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify LAML as the clearest survival context for RNASE12 RNA expression.
This table summarizes RNASE12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNASE12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE12 shows lower tumor expression in BRCA and PRAD. The BRCA box plot shows higher RNASE12 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p = .018).
This table shows molecular features associated with RNASE12 in patient tissues and cancer cell lines. In patient samples, RNASE12 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and STOMACH.
